EVOTEC Announces RESEARCH Agreement on Fragment-Based Drug Discovery with Cubist
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Evotec AG has announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., an acute care biopharmaceutical company located in Lexington, Mass., USA.
Cubist will use Evotec’s proprietary fragment screening technology, EVOlution™ to complement discovery research efforts in two of its antibacterials programs. EVOlution™ combines biochemical, nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) screening technologies for the screening of low molecular weight compounds and fragments.
By the combination of the orthogonal screening technologies, Evotec’s fragment screening platform is capable of screening a more diverse set of biological targets than other fragment screening approaches, as well as being able to screen the fragments in a high-throughput mode. The benefit of this is the ability to identify active fragments for numerous classes of biological targets in a short space of time.
In combination with fragment screening technology, Evotec will use its expertise in structural biology and protein crystallography in order to determine the 3-dimensional structure of the fragments bound to the targets of interest. To this end, Evotec will use its internal crystallography platform and will access the synchrotron technology of the Diamond Light Source, its partner for protein crystallography. By providing this technology in combination with its fragment screening, Evotec will supply high quality results to Cubist to enable the structure-driven identification of drug candidates for their priority antibacterial targets.
Dr Mark Ashton, Evotec’s EVP, Business Development commented: “We are pleased to be working with Cubist and look forward to identifying interesting fragments for their targets and to supporting them in their quest for new treatments for antibacterial diseases.”
No financial details are disclosed.
Cubist will use Evotec’s proprietary fragment screening technology, EVOlution™ to complement discovery research efforts in two of its antibacterials programs. EVOlution™ combines biochemical, nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) screening technologies for the screening of low molecular weight compounds and fragments.
By the combination of the orthogonal screening technologies, Evotec’s fragment screening platform is capable of screening a more diverse set of biological targets than other fragment screening approaches, as well as being able to screen the fragments in a high-throughput mode. The benefit of this is the ability to identify active fragments for numerous classes of biological targets in a short space of time.
In combination with fragment screening technology, Evotec will use its expertise in structural biology and protein crystallography in order to determine the 3-dimensional structure of the fragments bound to the targets of interest. To this end, Evotec will use its internal crystallography platform and will access the synchrotron technology of the Diamond Light Source, its partner for protein crystallography. By providing this technology in combination with its fragment screening, Evotec will supply high quality results to Cubist to enable the structure-driven identification of drug candidates for their priority antibacterial targets.
Dr Mark Ashton, Evotec’s EVP, Business Development commented: “We are pleased to be working with Cubist and look forward to identifying interesting fragments for their targets and to supporting them in their quest for new treatments for antibacterial diseases.”
No financial details are disclosed.
